Dasatinib: an inhibitor of tyrosine kinase (ITK) effective in acute transformations of CML and in Ph

被引：0
|
作者：
Rousselot, Philippe
机构：
来源：
HEMATOLOGIE | 2007年 / 13卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：282 / 283
页数：3
相关论文
共 50 条
  • [1] Ponatinib: An oral tyrosine kinase inhibitor for treatment of CML and Ph plus ALL
    Feret, Brett
    FORMULARY, 2013, 48 (05) : 169 - 170
  • [2] Cardiovascular Toxicities of Tyrosine Kinase Inhibitor in CML
    Master, Samip R.
    Mansour, Richard Preston
    BLOOD, 2020, 136
  • [3] Tyrosine kinase inhibitor for CML: all the same?
    Veltmaat, Lukas
    Cortes, Jorge
    BLOOD ADVANCES, 2024, 8 (20) : 5339 - 5341
  • [4] A CASE OF TYROSINE KINASE INHIBITOR (DASATINIB)-INDUCED ANGIOEDEMA
    Peterson, J.
    Toro, J.
    Welch, N.
    Lalmuanpuii, J.
    Tarbox, J.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S110 - S110
  • [5] Inhibition of PVR with a Tyrosine Kinase Inhibitor, Dasatinib, in the Swine
    Umazume, Kazuhiko
    Liu, LanHsin
    Scott, Patrick A.
    de Castro, Juan P. Fernandez
    McDonald, Kevin
    Kaplan, Henry J.
    Tamiya, Shigeo
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (02) : 1150 - 1159
  • [6] Dasatinib and nilotinib: effective alternatives to imatinib in CML and Ph-ALL?
    Nature Clinical Practice Oncology, 2006, 3 (10): : 526 - 526
  • [7] A STUDY OF END TYROSINE KINASE INHIBITOR IN CML (ENTIC) IN MALAYSIA
    Chong, SiewLian
    Asnawi, Asral Wirda Ahmad
    Wong, Tien Gen
    Selvaratnam, Veena
    Liew, Pek Kuen
    Abd Kadir, Sharifah Shahnaz Syed
    Ong, Tee Chuan
    Tan, Jerome
    Lau, Ngee Siang
    Tan, Sen Mui
    Goh, Ai Sim
    Lim, Soo Min
    Kori, Ahlam Naila
    Toh, See Guan
    Ng, Si Yuan
    Tan, Jenq Tzong
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2023, 45 : 23 - 23
  • [8] Predicting the Response of CML Patients to Tyrosine Kinase Inhibitor Therapy
    White, Deborah L.
    Hughes, Timothy P.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2011, 6 (02) : 88 - 95
  • [9] Predicting the Response of CML Patients to Tyrosine Kinase Inhibitor Therapy
    Deborah L. White
    Timothy P. Hughes
    Current Hematologic Malignancy Reports, 2011, 6
  • [10] Predicting the response of CML patients to tyrosine kinase inhibitor therapy
    White D.L.
    Hughes T.P.
    Current Hematologic Malignancy Reports, 2009, 4 (2) : 59 - 65
12345